Dr. Van K. Morris II, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Tennessee, Hsc, College of Medicine (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 94
Licensed in Texas since 2012, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: University of Tennessee, Hsc, College of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TX license P2738 (first issued 2012; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Physicians Referral Service (2,765 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 94
- Services billed
- 238
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 105 | 54 |
| Established patient office or other outpatient visit, 30-39 minutes | 80 | 40 |
| Established patient office or other outpatient visit, 20-29 minutes | 38 | 30 |
| New patient office or other outpatient visit, 60-74 minutes | 30 | 30 |
| Established patient office or other outpatient visit, 10-19 minutes | 15 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prochlorperazine Maleate Other prescribers in Houston, TX | 16 |
| Loperamide (loperamide hcl) Other prescribers in Houston, TX | 14 |
| Ondansetron Hcl Other prescribers in Houston, TX | 14 |
| Lonsurf (trifluridine/tipiracil hcl) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 34 payments worth $29,846 in total to this clinician.
| Incyte Corporation | $9,751 |
|---|---|
| BioNTech SE | $5,580 |
| GlaxoSmithKline, LLC. | $4,353 |
| E.r. Squibb & Sons, L.l.c. | $3,162 |
| AbbVie Inc. | $2,791 |
| Pfizer Inc. | $2,232 |
| Exelixis Inc. | $1,825 |
| Immunitybio, Inc. | $83.47 |
| Consulting Fee | $24,630 |
|---|---|
| Travel and Lodging | $2,560 |
| Honoraria | $1,650 |
| Food and Beverage | $1,006 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Incyte Corporation Dec 18, 2025 | Consulting Fee | $7,193 |
| BioNTech SE Jun 16, 2025 | Consulting Fee | $4,713 |
| GlaxoSmithKline, LLC. Apr 15, 2025 | Consulting Fee | $2,987 |
| AbbVie Inc. Jun 6, 2025 | Consulting Fee | $2,658 |
| E.r. Squibb & Sons, L.l.c. Jun 13, 2025 | Consulting Fee | $2,250 |
| Pfizer Inc. Jun 17, 2025 | Consulting Fee BRAFTOVI · ONCOLOGY | $2,160 |
| Exelixis Inc. May 22, 2025 | Honoraria CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,650 |
| Incyte Corporation Sep 19, 2025 | Consulting Fee | $1,370 |
| E.r. Squibb & Sons, L.l.c. Oct 20, 2025 | Consulting Fee | $900 |
| GlaxoSmithKline, LLC. Feb 24, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $545 |
All 19 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Incyte Corporation Dec 18, 2025 | Consulting Fee | $7,193 |
| Incyte Corporation Nov 14, 2025 | Travel and Lodging travel to Philadelphia, PA | $142 |
| Incyte Corporation Nov 13, 2025 | Travel and Lodging travel to Philadelphia, PA | $509 |
| Incyte Corporation Nov 13, 2025 | Travel and Lodging travel to Philadelphia, PA | $266 |
| Incyte Corporation Nov 13, 2025 | Travel and Lodging travel to Philadelphia, PA | $197 |
| E.r. Squibb & Sons, L.l.c. Oct 20, 2025 | Consulting Fee | $900 |
| Incyte Corporation Sep 19, 2025 | Consulting Fee | $1,370 |
| GlaxoSmithKline, LLC. Aug 22, 2025 | Consulting Fee | $400 |
| Pfizer Inc. Jun 17, 2025 | Consulting Fee BRAFTOVI · ONCOLOGY | $2,160 |
| BioNTech SE Jun 16, 2025 | Consulting Fee | $4,713 |
| E.r. Squibb & Sons, L.l.c. Jun 13, 2025 | Consulting Fee | $2,250 |
| AbbVie Inc. Jun 6, 2025 | Consulting Fee | $2,658 |
| BioNTech SE May 31, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $182 |
| BioNTech SE May 28, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $328 |
| BioNTech SE May 28, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $182 |
| Exelixis Inc. May 22, 2025 | Honoraria CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,650 |
| GlaxoSmithKline, LLC. Apr 15, 2025 | Consulting Fee | $2,987 |
| GlaxoSmithKline, LLC. Mar 24, 2025 | Travel and Lodging travel to Boston, MA · in-kind | $208 |
| GlaxoSmithKline, LLC. Feb 24, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $545 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 7 companies. The companies reported $825,020 in research payments for these studies, mostly to the institutions running them.
- First-in-Human, Phase 1,1b, Open-label, Multicenter Study of Bifunctional EGFR,TGF Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR-Driven Advanced Solid Tumors
Merck Sharp & Dohme LLC - A phase two, open label,multicenter,master protocol to evaluate the safety and efficacy of novel study interventions and combinations in participants with colorectal cancer cantor
AstraZeneca UK Limited - An openlabel multicenter randomized phase 3 study of firstline encorafenib plus cetuximab with or without chemotherapy versus standard of care therapy with a safety leadin of encorafenib and cetuximab plus chemotherap…
Pfizer Inc. - Phase Ib trial of encorafenib cetuximab and nivolumab in BRAF mutated metastatic colorectal cancer
E.r. Squibb & Sons, L.l.c. - A phase 2 randomized openlabel study of encorafenib and cetuximab plus pembrolizumab versus pembrolizumab alone in participants with previously untreated braf V600EMUTANT msi hdmmr metastatic colorectal cancer
Pfizer Inc. - BNT-122-01
BioNTech SE - BNT122
BioNTech SE - Phase 1 Study of Oral TP-1454
Sumitomo Pharma America, Inc. · Completed · NCT04328740 - An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line tre…
Novartis Pharmaceuticals Corporation - BNT314-02
BioNTech SE
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.